Showing results (11-20 of 21) with videos related to

Sort By:
Pageof 3
RMD Open|January 8, 2024
Difficult-to-treat psoriatic arthritis (D2T PsA): a scoping literature review informing a GRAPPA research projectShikha Singla, Andre Ribeiro, Murat Torgutalp, et al.
Rheumatology Advances in Practice|July 6, 2026
Recombinant zoster vaccine immunization rate in patients on Janus kinase inhibitors for rheumatologic and dermatologic conditionsJessica B Michaud, Ruta Brazauskas, Sarah Wigfield, et al.
Rheumatology (Oxford, England)|March 27, 2023
Unpublished clinical trials of common rheumatic diseasesConnor Pedersen, Shannon Tai, Erin Valley, et al.
The Journal of Rheumatology|July 1, 2026
GRAPPA 2025 Annual Meeting Report: Session on Geographic Variations in Psoriatic Arthritis/Psoriasis Care and Resource LimitationsElaine J Ma, Rose Boit, Ying Ying Leung, et al.
Internal and Emergency Medicine|June 7, 2026
Local LLM-based sentiment analysis of emotional patterns in complex-to-manage and treatment-resistant psoriatic arthritisVincenzo Venerito, Sergio Del Vescovo, M Cameron Hay, et al.
Rheumatology Advances in Practice|June 24, 2024
Deciphering difficult-to-treat psoriatic arthritis (D2T-PsA): a GRAPPA perspective from an international survey of healthcare professionalsAndre L Ribeiro, Shikha Singla, Vinod Chandran, et al.
Rheumatology (Oxford, England)|April 13, 2025
Deciphering difficult-to-treat psoriatic arthritis (D2T-PsA): insights from an international survey of patients with psoriatic arthritisAndre L Ribeiro, Shikha Singla, M Cameron Hay, et al.
Rheumatology (Oxford, England)|November 19, 2025
Key factors contributing to gender inequity in global rheumatology awards: a global survey analysisJessica Day, Lekshmi Minikumari Rahulan, Shikha Singla, et al.
Rheumatology and Therapy|November 14, 2025
On-Label Treatment Persistence Through 24 Months Among Patients with Active Psoriatic Arthritis Initiating Guselkumab or Subcutaneous Tumor Necrosis Factor InhibitorsPhilip J Mease, Jessica A Walsh, Timothy P Fitzgerald, et al.
Advances in Therapy|November 21, 2025
Real-World Comparison of On-Label Treatment Persistence Through 24 Months Between Patients with Psoriatic Arthritis Initiating Guselkumab or Subcutaneous Interleukin-17A InhibitorsPhilip J Mease, Jessica A Walsh, Timothy P Fitzgerald, et al.
Pageof 3